Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

NCT01919879 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
75
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

UNICANCER